Scope

Molecular Cancer Therapeutics publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology. To reflect the evolving field of therapeutics, the journal’s interest extends to all selective drugs including small molecule inhibitors, antibody–drug conjugates, antibody cytokine fusions, bispecific antibodies, cell therapies, gene therapies, radio-immunotherapeutics, vaccines, viral therapies, and other experimental approaches in oncology.

Molecular Cancer Therapeutics is abstracted and/or indexed in Current Contents/Clinical Medicine, MEDLINE, Science Citation Index, Scopus, and Web of Science.

Submission of Manuscripts

Online manuscript submission is welcomed at https://mct.msubmit.net. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal’s home page at https://mct.aacrjournals.org.

Publication Charges

Articles will be published with the understanding that the author(s) will pay both a publication fee plus a display item fee. For more detail, please see the Publication Fees and Reprints page which is available at https://aacrjournals.org/content/authors/publication-fees-and-reprints.

Subscription Information

AACR Members

AACR members may opt to receive either a print subscription with online access to content or an online-only subscription. Contact membership@aacr.org or visit the membership page at https://aacr.org for more information.

Nonmember Individuals

Subscriptions include online access only. Contacts listed below are for nonmember individual subscriptions.

USA and Rest of World (excluding Japan)
American Association for Cancer Research, 615 Chestnut Street, Philadelphia, PA 19106;
1-855-744-4667; pubsales@aacr.org

Japan
e-support@maruzen.co.jp;
journal@kinokuniya.co.jp; usaco@usaco.co.jp

International print subscriptions include cost of surface mail. Expedited mailing is available. Contact the American Association for Cancer Research for rates.

Site Licenses

For information about institutional site licenses, contact pubsales@aacr.org.

Single Issue Sales/Claims

Due to the impact of COVID-19, the AACR has discontinued single issue orders and fulfillment of claims through December 31, 2021.

Advertising Information

For information about advertising in AACR journals, contact The Walchli Tauber Group, Inc., 2225 Old Emmorton Road, Suite 201, Bel Air, MD 21205; (443) 512-8899; maura.paoletti@wt-group.com.

Copyright and Permissions

Content printed in or disseminated by Molecular Cancer Therapeutics is protected by copyright. Authors publishing in Molecular Cancer Therapeutics may either formally transfer copyright to the AACR or may select the Open Access option and publish the article under one of two Creative Commons Attribution license—Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) or Attribution 4.0 International (CC BY 4.0)—depending on funder requirements. Please visit https://aacrjournals.org/content/authors/copyright-permissions-and-access.